Dynus Medicaments Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 0.10 M
- Company Age 3 Year, 11 Months
- Last Filing with ROC 31 Mar 2022
- Revenue Growth %
- Profit Growth 115.86%
- Ebitda 118.81%
- Net Worth 3.97%
- Total Assets 2019.59%
About Dynus Medicaments
Dynus Medicaments Private Limited (DMPL) is a Private Limited Indian Non-Government Company incorporated in India on 20 February 2021 (Three years and 11 months 9 days old ). Its registered office is in Hyderabad, Telangana, India.
The Company is engaged in the Manufacturing Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2022. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Dinesh Gadde and Hema Gadde serve as directors at the Company.
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media-
Corporate Identity Details
- CIN/LLPIN
U17299TG2021PTC148859
- Company No.
148859
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
20 Feb 2021
- Date of AGM
30 Sep 2022
- Date of Balance Sheet
31 Mar 2022
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Who are the key members and board of directors at Dynus Medicaments?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Hema Gadde  | Managing Director | 20-Feb-2021 | Current |
Board Members (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Dinesh Gadde | Director | 20-Feb-2021 | Current |
Financial Performance of Dynus Medicaments.
Dynus Medicaments Private Limited, for the financial year ended 2022, experienced no change in revenue, with a 0% increase. The company also saw a substantial improvement in profitability, with a 115.86% increase in profit. The company's net worth moved up by a moderate rise of 3.97%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Dynus Medicaments?
Unlock access to Dynus Medicaments's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Dynus Medicaments?
Dynus Medicaments has a workforce of 0 employees as of Apr 09, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Dynus Medicaments, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Dynus Medicaments's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.